congenital thrombotic thrombocytopenic purpura
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
MHRA approves Leqselvi for severe alopecia areata
Around 30% of patients saw 80% more scalp hair after 24 weeks of treatment
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity
Obesity affects approximately 15 million people in the UK
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment
The MHRA approval for IV dosing comes following positive results from the global phase 3 trial
MHRA marks 100 years of patient safety through biological standards
The UK regulator highlights its century-long role in establishing safety and consistency benchmarks
MHRA and FDA expand collaboration on AI and medtech regulation
National Commission on the Regulation of AI in Healthcare brings together UK and US experts